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Prostate cancercritical role in the development and maintenance of cancers in the prostate.
Earlier, we have shown that Cdc6, a regulatory protein for initiation of DNA replication, is down regulated in
androgen-insensitive prostate cancer cells. In this report, we studied the involvement of androgen, mediated
through androgen receptor (AR) in regulation of Cdc6 expression. Our results demonstrated that androgen
treatment stimulated Cdc6 expression in xenograft tumors and androgen-sensitive prostate cancer cells. We
also showed that androgen treatment stimulated Cdc6 transcription through possible interaction of AR with
the ARE sequence in the Cdc6 promoter and that the stimulatory effect of androgen required intact E2F
binding sites in the promoter. Androgen treatment differentially altered nuclear availability of E2F1 and E2F3,
and increased the amount of hypophosphorylated retinoblastoma protein (pRb) in the nucleus in a time
dependent fashion. We further showed that AR interacted with E2F transcription factors in a ligand-
independent manner and that ligand-bound AR was less efﬁcient in interacting with E2F proteins. DNA–
protein interaction assays indicated that androgen treatment altered binding of E2F1 to the Cdc6 promoter in
prostate cancer cells. We conclude that AR regulates Cdc6 transcription through interaction with the Cdc6
promoter, and complex formation with E2F1 and E2F3 in a differential manner.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionAndrogens and androgen receptor (AR) play a pivotal role in
maintenance and progression of cancers in the prostate [1]. Because
neoplastic prostates depend on circulating androgens for their growth
and survival androgenwithdrawal is one of the current treatments for
prostate cancer. Androgen receptor requires androgen for proper
functioning as a transcription factor and regulates a wide variety of
genes upon ligand binding [2,3]. In mature prostate, activated AR
maintains a constant cell population by stimulating cell proliferation
and apoptosis [4]. It has been documented that AR mediates its cell
proliferating effect through activation of cell cycle regulatory genes,
such as CDK2 and CDK4 [5,6]. In the prostate cancer CWR22 xenograft
models, levels of CDK2, CDK4, cyclin B and cyclin E decreased after
castration but were restored following treatment with testosterone
propionate [7].
An important aspect of the AR mediated cell cycle regulation is its
cyclical activation during cell cycle phases, which triggers transcrip-
tion of androgen-sensitive genes. The transcriptional activity of AR is
abolished at the G1/S transition but reappeared in the S phase. AR isr Biology and Microbiology,
ay, Orlando, FL 32826, USA.
.
l rights reserved.predicted to be transcriptionally active at G0 through its interaction
with the hypophosphorylated Rb [8]. Transcription activation of the
AR-responsive genes is mediated through binding of the activated AR
with androgen response elements (ARE) in the promoters. In the
absence of ligands, cytoplasmic AR remains as an inactive complex
with the heat shock protein 90. Upon binding to androgens, AR is
released from the inhibitory complex, translocates to the nucleus and
binds to the ARE as a dimer [6,9]. In addition, transcriptional activity of
AR is modulated by a number of coactivators or corepressors including
cyclin D1 and cyclin E [10–13]. A number of transcription/transacting
factors such as Oct1, NF-kB and AP1 also act as coactivators or core-
pressors of AR [14–16]. Indirect evidence indicated that AR also
regulates activation of E2F transcription factor through modulation of
Rb phosphorylation in a ligand-dependent manner [17]. However, the
exact mechanism of AR mediated regulation of E2F function and the
roles of Rb and androgen are unclear as earlier studies have shown
that AR physically interacts with hypophosphorylated Rb in a ligand-
independent manner [18].
Our earlier studies have indicated that CDC6, a highly conserved
cell cycle regulatory protein is down-regulated in androgen-insensi-
tive prostate cancer cells and that the reduced expression of CDC6 is
due to inefﬁcient transcription [19]. Recent studies also have shown
that treatment with anti-androgen bicalutamide inhibited progres-
sion of cells through G1/S phase and inhibited expression of CDC6, in
LNCaP cells [20]. CDC6 plays a critical role in restricting DNA repli-
cation to once per cell cycle [21] and helps to establish prereplicative
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(ORC) [22] by recruiting minichromosome maintenance (MCM)
proteins and other factors [23–25]. In normally proliferating cells,
the concentration of CDC6 is tightly regulated for proper progression
of cells through the phases of cell cycle.
Regulation of Cdc6 gene expression follows the cyclical pattern of
G1, S, G2 and M phase. In human cells, Cdc6 is transcribed in mid to
late G1 in E2F-regulatory manner [21,26,27]. Cdc6 promoter contains
three E2F binding sites and ectopic expression of E2F stimulates Cdc6
promoter activity following serum stimulation. G1 cyclins and CDKs in
turn regulate transcriptional activity of E2F through phosphorylation
of Rb family of proteins. Importantly, E2F acts as a positive and
negative regulator of Cdc6 transcription depending on the cell cycle
stages. In early phases of the cell cycle, E2F sites are occupied by pRb,
p107, and/or p130 bound to E2F-DP inhibitory complexes. It has been
proposed that Cdc6 transcription in mid to late G1 phase is achieved
by possible displacement of the inhibitory complex by other
transcription factors [28].
In this report, we provide evidence that androgen and AR regulates
Cdc6 transcription and that the effect of androgen is mediated through
modulation of E2F dependent transcription of Cdc6 gene. Our study
also demonstrates that androgen modulates binding of E2F transcrip-
tion factors to Cdc6 promoter.Fig. 1. Differential expression of CDC6 in mouse tumors and transfected cells. A and B: Se
B: Densitometric analysis of the relative concentration of Cdc6mRNA. Data represents mean
vs. androgen supplemented). C and D: Immunoblot (C) and densitometric (D) analysis of CD
sets of tumors (p values: ⁎0.014 castrated vs. untreated; ⁎⁎0.02 castrated vs. androgen supplem
18S rRNA and GAPDH were used as the loading controls.2. Materials and methods
2.1. Cell lines and tumors
Two commercially available cells lines PC3 and LNCaP (ATCC) were
maintained in Ham's F-12 (PC3) and RPMI1640 (LNCaP) media, contain-
ing 10% fetal bovine serum (FBS) and penicillin/streptomycin. PC3AR and
PC3Neo (a gift from Kerry, Burnstein, University of Miami) [29] were
maintained in RPMI 1640 containing 10% FBS, 1% antibiotic/antimycotic
(Invitrogen) andG418 (350πg/ml). CWR22 xenograft tumors (a gift from
William Grizzle, University of Alabama at Birmingham) [30,31] were
obtained from untreated mice, from 28 days post castrated mice and
from28dayspost castratedmicewith slow releasing testosteronepellets
implanted after 21 days.
2.2. Semiquantitative RT-PCR
Total RNA from tumor tissues was used for RT reaction using oligo
d(T) primer, 18S RNA primer pairs and their compertimers (Quantum
RNA, Ambion), and Superscript II reverse transcriptase (Invitrogen). The
18S primers were used to generate an internal control transcript of
489 bp. A Cdc6 gene speciﬁc primer pairs (F 5′CTGGAGTTTGCTGCTG-
CCGCT3′ andR5′GAGCACCAGAAAGGTAAAGGC)wasused to amplifyanmiquantitative RT-PCR of Cdc6 transcripts in CWR22 mice tumors. A: Autoradiogram,
±SD of three separate analyses (p values: ⁎0.05 castrated vs. untreated; ⁎⁎0.04 castrated
C6 concentration in crude extracts of CWR22 tumors. Data represents mean±SD of two
ented). E: Immunoblot analysis of CDC6 concentration in PC3Neo, PC3AR and PC3 cells.
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blot using Cdc6 and 18S ribosomal RNA cDNAs as probes. Positive
signals were quantiﬁed in a Phosphorimager (Amersham Biosciences)
and normalized with the relative values of 18S rRNA signals.
2.3. Preparation of crude cell and nuclear extract
PC3AR, PC3Neo and LNCaP cells were grown to 80% conﬂuency and
harvested using freeze—thaw cycle in a lysis buffer (50 mM Tris—HCl,
pH 8.0, 120 mM NaCl, 2.5 mM EDTA, pH 8.0, 1 mM phenylmethylsul-
fonyl ﬂuoride, 0.4% Nonidet P-40, and 2ml/ml of the protease inhibitor
mixture Set III (Calbiochem)). Crude cell lysates were centrifuged at
16,000 g for 10 min at 4 °C to remove cellular debris. For nuclear
extract, 100 πl of packed cell volume of each cell and nuclear extrac-
tion reagent (NE-per Pierce) were used according to the manufac-
turer's protocol. Nuclear extracts from mouse tumors were prepared
using a nuclear extraction kit from Panomics according to the
manufacturer's protocol. Nuclear pellets were collected and lysed by
vortexing in a lysis buffer NER (Pierce), and soluble proteins were
separated in the supernatant by centrifugation at 14,000 g for 10 min
at 4 °C. Supernatants were stored at 80 °C until use for Western blot
analysis.
2.4. Immunoblot and Immunoprecipitation
Total cell extracts from asynchronous cultures of PC3AR, PC3Neo
and LNCaP cells were used for immunoblot analysis using a standard
procedure. Total protein (50 πg) or nuclear extracts (20 πg) and
antibodies against CDC6 (Oncogene Research Products, La Jolla, CA),Fig. 2. Treatments of DHT/R1881 increased CDC6 expression in PC3AR and LNCaP cells. Cru
immunoblotted with anti-CDC6 and anti-GAPDH antibodies. GAPDH concentration was us
concentration in untreated and treated cells after normalization with values of GAPDH. Valu
treated; ⁎⁎≤0.055 treated vs. 0 h; •b0.0448 untreated vs. 0 h). D: Western blot of CDC6 in th
different times. E: Densitometric analysis of the relative concentration of CDC6. Gamma tubu
values: ⁎=0.005; ⁎⁎≤0.0048; •≤0.0076).E2F1 (Santa Cruz Biotechnology Inc., Santa Cruz, CA), E2F3 (Santa Cruz
Biotechnology, Inc.), pRb (Cell Signaling), and ppRb (Cell signaling)
were used to monitor expression of speciﬁc proteins. A chemilumi-
nescence detection kit (Pierce) was used to detect positive signals
recognized by speciﬁc antibodies using either a goat anti-mouse or a
goat anti-rabbit horseradish peroxidase-conjugated secondary anti-
body. When indicated, PC3AR or LNCaP cells were maintained in
charcoal-stripped serum (CSS) containing medium for 48 h and
treated with DHT (5 nM) or R1881 (1 nM). Cells were harvested at
different time points for preparation of crude cell or nuclear extracts
as described earlier. For immunoprecipitation, nuclear extracts from
freshly harvested cells were diluted in RIPA buffer containing protease
inhibitor mixture Set III (Calbiochem) and treated with anti-AR
antibodies (US Biologicals) using standard protocol. Antigen–antibody
complexes were immunoprecipitated using protein A/G PLUS agarose
beads and immunoblotted using speciﬁc antibodies.
2.5. Androgen treatment and expression of luciferase gene
The Cdc6 promoter-luciferase construct, containing Cdc6 promoter
sequence spanning from positions −1436 to +218 was cloned into
pGL3 basic ﬁreﬂy luciferase vector (Promega) (Cdc6WT) as described
[19] and used for transient transfection and luciferase assays. A Cdc6-
luciferase construct (Cdc6AREM) containing deleted putative andro-
gen response element (ARE) (AGAACATAATATTC) (between −748 and
−733 bases was prepared using a PCR-based mutagenesis method
described in the Quik-Change kit (Stratagene). Cdc6-luciferase con-
struct containing point mutations in the two proximal E2F binding
sites at positions −43 to −36 and −8 to −1 from the transcription startde cell extracts of PC3AR either left untreated (A) or treated (B) with DHT (5 nM) were
ed as the loading control. C: Densitometric analysis of the relative alteration in CDC6
es represent mean±SD of three different experiments (p values: ⁎≤0.0476 untreated vs.
e nuclear extracts of LNCaP cells either left untreated or treated with R1881 (1 nM) for
lin was used as the loading control. Data shows mean±SD of three different analyses (p
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transfection. Cdc6-luciferase construct containing deleted putative
ARE in addition to point mutations in E2F binding sites (E2F/ARE DM)
was also prepared and used for transfection. LNCaP cells were grown
to 75% conﬂuence and maintained in CSS medium for 48 h. Next, cells
were transfected with the pGL3 constructs and pRL-TK (Promega)
as an internal control vector using LipofectAMINE (Life Technologies)
according to the manufacturer's speciﬁcation. Transfected cells were
maintained in CSS culture medium and either treated with R1881
(1 nM) or left untreated for 24 h. Cells were harvested at 48 h after
transfection and luciferase expressions were monitored using a Dual
Luciferase assay kit (Promega) according the supplier's protocol.
Relative luminescence from the expressed luciferase was normalized
with the expression of Renilla luciferase. Transfection efﬁciencies
were calculated as the relative luminescence unit (RLU) ratio of pGL3
constructs over that of pGL3 basic vector.
2.6. Chromatin immunoprecipitation
LNCaP cells were maintained in CSS medium and either treated
with R1881 (1 nM) or left untreated for 24 h. Before harvesting, cells
were cross-linked with 1% formaldehyde containing culture medium
for 10 minwith shaking at room temperature. Cells were washed with
PBS and treatedwithGlycine stop-ﬁx buffer (ChIP-IT Express kit, Active
Motif, Carlsbad, CA) for 5min at room temperature. Cells were washed
and processed for nuclei isolation followed by chromatin isolation and
shearing using a kit (ChIP-IT Express kit, Active Motif, Carlsbad,
CA) according to the manufacturer's speciﬁcation. Chromatinwas pre-
cleared with salmon sperm DNA/protein G and subjected to immuno-
precipitation using anti-E2F1 (SC-193X, Santa Cruz Biotechnology),
anti-E2F3 (SC-878x Santa Cruz Biotechnology) or anti-AR (A2281x, US
Biologicals) antibodies (2 πg/ChIP reaction) in ChIP buffer (ChIP-IT kit)Fig. 3. Effects of androgen, deletion of ARE and mutation in E2F binding sites on Cdc6 pr
constructs containing wild type (A and B) or ARE deleted Cdc6 promoter (AREM) (B) treatedw
comparison. Relative luciferase activity in LNCaP cells following transfection of Cdc6 promot
or with deleted ARE sequence (D). Data represents mean±SD of four separate experiments.according to the manufacturer's protocol. Immunoprecipitated DNA
was eluted from protein G beads; reverse cross-linked, treated with
proteinase K and puriﬁed using DNA puriﬁcation columns. Puriﬁed
DNA (5 πl) was used for PCR ampliﬁcation using primers (10 pmol)
speciﬁc for ampliﬁcation of E2F (betweenposition −84 and +103 bases)
[32] (F: 5′-AAAGGCTCTGTGACTACAGCCAAT-3′, R: 5′-GTGCAG-
GATCCTTCTCACGTC TCTCAC-3′) and AR (between positions −831 and
−564 bases) (F: 5′-GGCCCTGAAA CCCTAGTGTTTCGCCAT-3′, R: 5′-
GGATCCAGATCTCCTGATGGCTGAAC-3′) binding sites on Cdc6 promo-
ter. Ampliﬁed products were analyzed on 2% agarose gel.
3. Results
3.1. CDC6 expression was upregulated in prostate tumor cells in response
to androgen treatment or expressing a functional AR
Our earlier studies have shown a differential expression of CDC6
between androgen-sensitive LNCaP and -insensitive PC3 cells. To under-
stand any relation between androgen sensitivity of the prostate tumors
and CDC6 expression, we studied the proﬁle of CDC6 expression in
CWR22 xenograft tumors with or without androgen deprivation and
following supplementation of androgen. Cdc6 mRNA concentration in
the tumors from castrated mice showed a 3-fold reduction (p=0.05),
which was restored to a level higher than the untreated ones upon
implantation of a testosterone pellet (Fig. 1A and B). Western blot
analysis of the amounts of CDC6 (62 kDa) in tumors supported the RT-
PCR results showing a signiﬁcant reduction (p=0.014) following
castration (Fig. 1C and D). CDC6 expression also has been restored
partially in PC3AR cells, which express a functional AR and PSA com-
pared to the parental PC3 cells and vector only PC3 cells (PC3-Neo)
(Fig. 1E). Next, we studied the effect of treatment of androgen or
androgen analog R1881 on CDC6 expression using total extracts ofomoter activity. Relative luciferase activity in LNCaP cells transfected with luciferase
ith R1881 (1 nM) for 24 h or left untreated. Basic and control plasmids were also used for
er-luciferase constructs containing two point mutations in E2F binding sites without (C)
Fig. 4.Mutation in E2F binding sites abrogated repression of Cdc6 promoter activitywith
or without an intact ARE. Relative luciferase activity in LNCaP cells transfected with
luciferase constructs containing wild type; E2F binding sites mutated; or E2F/ARE
doublymutated Cdc6 promoters (E2FM and E2F/AREDM) and treatedwith R1881 (1 nM)
for 24 h or left untreated. Data represents mean±SD of four separate experiments.
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concentration of DHT (5 nM) and R1881 (1 nM) for treatment of PC3-AR
and LNCaP cells respectively [32,33]. Western blots followed by
densitometric analyses of a time course study indicated a biphasic
increase in CDC6 expression in total cell lysates following treatment
with DHT (Fig. 2A, B and C) at 2 h and 24 h. Treatment with R1881 also
increased CDC6 concentration at 24 h (p=0.055) in the nuclear extracts
of LNCaP cells (Fig. 2D and E). The concentration of CDC6 in both total-
and nuclear extracts declined at 48 h after androgen treatment. No
increase in CDC6 concentrationwas observed following treatment with
R1881 at 0.1 nM concentration (data not shown).
3.2. Androgen stimulated Cdc6 transcription through interaction of AR
with Cdc6 promoter
Sequence analysis of the Cdc6 promoter indicated the presence of a
putative ARE in the 5′ ﬂanking sequence of Cdc6 promoter between
positions −748 and −733,which suggested a possibility of ARmediated
regulation of Cdc6 transcription. To determine whether the effect of
androgen treatment is through activation of the Cdc6 promoter we
monitored expression of luciferase reporter gene driven by Cdc6
promoter in LNCaP cells following treatment with R1881 at different
times after transient transfection. We used R1881 at 1 nM concentra-
tion as AR is transcriptionally active and stimulates PSA transcription in
LNCaP cells at this concentration [33,34]. Our results showed a 2.5–3.7-
fold increase in RLU following R1881 treatments (Fig. 3A and B). To
conﬁrm the involvement of ARE in androgen-induced Cdc6 transcrip-
tion activation we tested the effect of androgen following deletion of
the ARE. A signiﬁcant loss of induction of Cdc6 transcriptionwas noted
in cells transfected with the construct containing Cdc6 promoter with
deleted ARE (Fig. 3B). A modest 1.4 to 2.0-fold increase in RLU was
noted in these cells following R1881 treatment. This result conﬁrms
that the putative ARE sequence is indeed utilized by the AR.
Interestingly, deletion of the ARE did not abrogate the effect of
androgen completely suggesting a cooperative transcriptional activity
of AR apart from its DNA binding activity.
3.3. Stimulation of Cdc6 transcription by androgen requires intact E2F
binding sites in the Cdc6 promoter
Because androgen has been shown to regulate transcriptional
activity of E2F transcription factor [34] and given the fact that Cdc6
transcription is regulated by E2F [27] we determined whether AR
mediated stimulation of Cdc6 transcription is dependent on DNA–
protein interaction between Cdc6 promoter and E2F. We monitored
luciferase expression following transfection of the promoter construct
Cdc6E2FM containing point mutations in two proximal E2F binding
sites. Our results showed that the construct with mutated E2F binding
sites failed to replicate the stimulatory effect of R1881 on Cdc6 tran-
scription (Fig. 3C). Luciferase expression following transfection of
Cdc6E2F and ARE double mutant construct (Cdc6E2F/AREDM) did not
indicate the stimulatoryeffect of R1881 onCdc6 transcription either (Fig.
3D). When RLU of Cdc6E2FM and Cdc6E2F/AREDM were compared to
the wild type Cdc6 promoter a 4-fold increase in RLU could be noted in
untreated LNCaP cells, which did not change signiﬁcantly following
R1881 treatment (Fig. 4B). These experiments further conﬁrmed the
repressor effect of E2F on Cdc6 promoter and that the increased
promoter activity in the absence of the inhibitory effect of E2F binding to
the proximal E2F binding sites was not mediated through AR and Cdc6
promoter interaction or through the indirect effect of R1881 treatment.
3.4. Androgen treatment was associated with altered levels of the E2F
proteins in the nucleus
Earlier studies have shown differentiable roles of different E2F
family members on transcription of Cdc6 gene [35]. E2F3 has beenshown to bind to the Cdc6 promoter and stimulate transcription
during G/S phase. The other family member E2F1 instead forms a
repressor complex with Rb, which occupies Cdc6 promoter and
prevents untimely transcription of Cdc6 gene at G0 [35–37]. Because
androgen has been shown to have inﬂuence on expression and
transcriptional activities of E2F1 [34] we intended to monitor the
effect of R1881 treatment on nuclear concentration of E2F1 and E2F3
in LNCaP cells. Our results showed that in untreated LNCaP cells, E2F1
concentration increased gradually from 0hr reaching a peak at 48h
before declining sharply at 72 h. Cells treated with R1881 instead,
showed an oscillation in E2F1 concentration between 24 h and 72 h,
which varied between 0.8 and 1.3-fold of the E2F1 concentration at
the 0 h (p≤0.0445) (Fig. 5A and B), but no signiﬁcant difference was
noted between treated and untreated cells. When compared with the
untreated cells, nuclear E2F1 concentration decreased in the treated
cells at 48 h but restored to the initial level at 72 h showing a dif-
ference of 6.5-fold (p=0.0184) from the untreated cells at 72 h. The
concentration of nuclear E2F3 showed a signiﬁcant increase at 24 h in
treated cells compared to the untreated ones (p=0.013) but decreased
steadily thereafter reaching a nadir at 72 h (Fig. 5C and D). Untreated
LNCaP cells whereas, maintained a steady concentration of nuclear
E2F3 till 48 h but showed a reduced level of E2F3 at 72 h. No change in
E2F1 or E2F3 expressions at 24 h in total cell lysates of LNCaP cells
treated with a lower dose of R1881 (0.1 nM) was noted (data not
shown).
Analysis of Rb phosphorylation indicated a decline in the hyper-
phosphorylated Rb (ppRb) at 24, 48 and 72 h but a sharper declinewas
noted following R1881 treatment (Fig. 5C and E). Consequently, a
Fig. 5. R1881 treatmentmodulates levels of E2F transcription factors and Rb in the nucleus of LNCaP Cells. A, C and E:Western blots of nuclear E2F1 (A), E2F3 (C), pRb (E) and ppRb (E)
levels in LNCaP cells at different times following R1881 treatment. Gamma tubulinwas used as the loading control. B, D, and F: Densitometric analysis of the relative concentration of
E2F1 (B), E2F3 (D) and pRb/ppRb (F) after normalization with the values of gamma tubulin. Data represent mean±SD of three separate analyses for all proteins (p values: ⁎≤0.0346
untreated vs. treated; ⁎⁎≤0.0445 treated vs. 0 h; •≤0.0346 untreated vs. 0 h).
Fig. 6. Complex formation between AR and E2F3. A: Immunoblot analysis of AR in
nuclear extracts of LNCaP cells with or without treatment with R1881 for 24 h. Gamma-
tubulin was used as the loading control. B: Immunoprecipitation followed by immu-
noblot analysis of AR using anti-AR antibody from nuclear extracts of LNCaP cell with or
without treatment with R1881. C: Immunoprecipitation followed by immunoblot
analysis of E2F3 from nuclear extracts of LNCaP cells with or without treatment with
R1881. sup: Supernatant.
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sphorylated Rb (pRb) was noted in the R1881-treated nuclear extracts
at 24 h, which reduced progressively at 48 h and 72 h (Fig. 5F and G). In
untreated cells, a delayed increase in pRb concentration was noted at
48 h, which again reduced at 72 h.
3.5. Androgen receptor physically interacts with E2F transcription factor
Retinoblastoma protein has been shown to bind to AR and
stimulate its transcription activity through interaction with general
transcription factors [18]. Because pRb regulates transcriptional
activities of E2F family proteins we intended to monitor whether
there is any direct or indirect interaction between AR and E2F proteins
using coimmunoprecipitation method (Fig. 6). Western blot analysis
showed an increased accumulation of AR in the nucleus following
treatment with R1881 (Fig. 6A). Immunoprecipitation of AR from the
nuclear extracts using an anti-AR antibody also showed enrichment of
AR following R1881 treatment (Fig. 6B). Western blot analysis of the
AR immunoprecipitation complex, using an anti E2F3 antibody,
showed that E2F3 was pulled down along with AR indicating a
distinct association between AR and E2F3 in LNCaP cells (Fig. 6C).
Interestingly, unliganded AR is more efﬁcient in enriching E2F3 in
immunoprecipitated complex, suggesting that AR–E2F3 interaction is
independent of ligand binding. Although treatment with R1881
increased the concentration of E2F3 in nuclear extracts ligand-
Fig. 7. Binding of AR, E2F1 and E2F3 transcription factors to Cdc6 promoter changes
following R1881 treatment. Chromatin immunoprecipitations using nuclei of LNCaP
cells were performed with antibodies speciﬁc for AR, E2F1 and E2F3 as indicated and
resulting immunoprecipitates or input DNA were ampliﬁed using primer pairs
corresponding to ARE and E2F binding sites on Cdc6 promoter. LNCaP cells were
treated with R1881 (1 nM) or left untreated for 24 h before harvested for ChIP assay.
Fig. 8. Proposed model of AR mediated Cdc6 transcription following treatment with
androgen (R1881). The diagram is not to the scale and does not show dimerization of
the transcription factors.
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Similar association between AR and E2F1 was also noted in
coimmunoprecipitation experiments (data not shown).
3.6. Androgen facilitates binding of AR and E2F3 to Cdc6 promoter
To determine the promoter occupancy of AR and E2F family
transcription factors we used ChIP analyses using R1881 treated and
untreated LNCaP cells. We have designed primers to cover 267 bp
regions between −732 and −467 bases. Our results showed binding of
AR with the Cdc6 promoter spanning the area containing the putative
ARE (Fig. 7A). R1881 treatment facilitated binding of AR to Cdc6
promoter as the intensity of the AR amplicon from AR ChIP DNA of
R1881 treated LNCaP extracts was substantially higher compared to
that of untreated extracts. R1881 treatment also enhanced binding of
E2F3 but prevented binding of E2F1 to the E2F binding sites in Cdc6
promoter between −43 and −1 bases [38]. (Fig. 7B) as noted by
differential ampliﬁcation intensities of the amplicons obtained from
PCR reactions using E2F1 ChIP and E2F3 ChIP of LNCaP extracts. No
amplicon could be detected when E2F1 ChIP DNA from R1881 treated
nuclear extracts was used. This observation conﬁrms that the putative
ARE in the Cdc6 promoter is indeed a binding site of AR and that the
occupancy of the proximal E2F binding site on Cdc6 promoter by E2F1
and E2F3 is modulated by R1881 treatment.
4. Discussion
In this study, we investigated the involvement of androgen and AR
in regulation of Cdc6 transcription in prostate tumor cells. Our study
indicated that androgen supplementation or expression of a func-
tional AR in PC3 cells signiﬁcantly increased Cdc6 mRNA and protein
concentrations, and androgenwithdrawal by castration reduced CDC6
expression. This observation is in support of our earlier ﬁnding that
CDC6 expression is down regulated in PC3 prostate cancer cells [19],
which does not express a functional AR. Treatment of androgen also
increased total concentration and nuclear accumulation of CDC6 in
both PC3AR and androgen-sensitive LNCaP cells, respectively. Our
observations on the effect of androgen on Cdc6 expression are in
agreement with studies showing that functional down regulation of
AR using genistein or bicalutamide was associated with decreased
expression of CDC6 in LNCaP cells [20,39,40]. The present study
showed a direct involvement of AR in transcriptional regulation of
Cdc6 in androgen-sensitive prostate cancer cells.
In our earlier studies, we have noted that inclusion of 403 bases
(between −391 and −794), which contains a putative ARE sequence in
the Cdc6 promoter-luciferase constructs improved luciferase expres-sion 4–5-fold [19]. In this study, we provide evidence of androgen-
induced stimulation of Cdc6 transcription through possible interaction
of AR with the putative ARE present in the Cdc6 promoter as deletion
of the ARE sequence signiﬁcantly attenuated this effect. Occupancy of
theARE sequencebyAR is conﬁrmedbyourChIP analysiswhich showed
enriched binding of AR with the region spanning ARE upon R1881
treatment. Interestingly, luciferase reporter assays also indicated a
possible functional co-operativity between AR with other transcription
factors in regulation of Cdc6 transcription as the construct with deleted
ARE showeda 2.0-fold increase inRLU, althoughmuch less than thewild
type promoter, following treatment with R1881.
One of the key transcription factors that regulate Cdc6 transcrip-
tion is E2F. It has been proposed that in quiescent stages, two proximal
E2F sites are occupied by E2F–Rb repressor complexes possibly E2F1–
Rb, which upon serum stimulation become dislodged by some un-
known mechanism. This allows binding of the other family member,
E2F3 as Rb becomes hyperphosphorylated by Cyclin D1/CDK2 and
stimulates Cdc6 transcription [35,36]. In transiently transfected
asynchronous cell population, we noticed an increased transcription
of Cdc6 upon point mutations in two proximal E2F binding sites that
prevented E2F binding. This suggests abrogation of the repressor
effects of Rb–E2F complex on Cdc6 transcription, which is in
agreement with earlier studies done in our laboratory and by others
[36,37]. Similar increase in luciferase expression was noted upon
removal of the ARE sequence which indicates that the increased Cdc6
transcription upon mutation of the E2F binding site does not require
intact ARE sequence. This is further conﬁrmed by the experiment
showing no additional increase in Cdc6 transcription in Cdc6E2F or
Cdc6E2FAREDM cells following treatment with R1881. It is possible that
androgen-induced stimulation ofCdc6 transcription ismediated through
removal of the E2F1–Rb inhibitory complex, which in turn indirectly
facilitates binding of free E2F3 that acts as a transcription activator.
Furthermore, our immunoprecipitation data indicated a ligand-inde-
pendent interaction of AR with E2F proteins, which could be through a
direct binding or through the binding of Rb–E2F complex as AR has been
shown to binds to pRb also in a ligand-independent manner [18].
Our DNA/protein immunoprecipitation assays showed that andro-
gen treatment reduced DNA binding of E2F1 transcription factor,
which is in support of the earlier studies showing decreased E2F1
transcriptional activity following treatment of LNCaP cells with R1881
[34]. Based on our observation and published reports, we propose a
model of androgen-induced Cdc6 transcription (Fig. 8). In untreated
LNCaP cells, pRb forms a complex with E2F and acts as a repressor of
Cdc6 transcription through the occupancy of E2F binding sites.
Androgen treatment increases nuclear accumulation of the ligand-
1744 I. Mallik et al. / Biochimica et Biophysica Acta 1783 (2008) 1737–1744bound AR, which then binds to the ARE sequence of the Cdc6
promoter. DNA-bound AR then dislodges Rb–E2F1 repressor complex
throughbindingof thepRb–E2F complex,whichpossibly occurs through
its N-terminal domain close to its DNA binding domain as suggested
earlier [18]. Removal of the repressor complex then allows free E2F
family proteins, possibly E2F3, to bind to the E2Fbinding sites in theCdc6
promoterand thereby, activates its transcription.Thismodel is supported
by the data obtained by ChIP analysis showing that R1881 treatment
prevented binding of E2F1, while enhancing binding of E2F3 to the Cdc6
promoter. A signiﬁcant increase in nuclear accumulation of hypopho-
sphorylatedRb (pRb) at 24h and subsequentdecrease inphosphorylated
Rb (ppRb) concentration at 24, 48 and 72 h in R1881 treated cells
increases the availability of pRb. Given that the binding of pRb with AR
stimulates its transcriptional activity the availability of unphosphory-
latedRb aids in bindingof co-activators to AR for transcription activation,
which includes TFIIF, TBP [41], and TAFII250 [42].
AlthoughARbinds toRb through its N-terminal domain it is unclear
whether the endogenous AR–Rb interaction depends on binding of AR
toAREupon ligand binding. Our results indicated a reduced interaction
of AR with E2F3 following androgen treatment suggesting a possible
enrichment of free E2F3 proteins in the nucleus. Furthermore,
androgen treatment showed an increased nuclear concentration of
E2F3 at 24 h. Because androgen treatment increased nuclear
accumulation of ligand-bound AR it could be speculated that liganded
AR is responsible for sequestration of hypophosphorylated Rb [18] and
increased availability of free E2F3, which facilitates its binding to the
Cdc6 promoter. Although we noted an increase in LNCaP cell growth
at 24 h following R1881 treatment using MTTassays (data not shown),
which is in support of the published study [33], in-depth under-
standing of the speciﬁc function of AR in cell cycle regulationwith the
context of Cdc6 transcription requires further study.
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